Form 4: ADMA Biologics COO Granted Significant Equity Awards

ADMA Biologics' COO and SVP of Compliance, Kaitlin M. Kestenberg-Messina, was granted 91,631 restricted stock units and 144,230 stock options.

Summary

• Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, Inc. (ADMA), reported an acquisition of equity securities.
• On February 9, 2026, Kestenberg-Messina acquired 91,631 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs will vest quarterly on each annual anniversary of the grant date over four years, subject to continued service.
• Following this transaction, Kestenberg-Messina beneficially owns 580,321 shares of non-derivative Common Stock, which includes various unvested RSUs from prior grants and 194,166 directly owned shares.
• On the same date, Kestenberg-Messina also acquired 144,230 stock options with an exercise price of $16.37.
• These stock options vest over four years: 25% on the one-year anniversary of the grant date, and the remaining 75% monthly over the subsequent three years, becoming fully vested by February 9, 2030.
• The stock options have an expiration date of February 9, 2036.
• All equity grants are in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine disclosure. The grant of equity awards aligns executive incentives with shareholder interests, which is generally favorable, but it is a standard compensation event rather than a significant operational or financial announcement.

Positives

• The grant of restricted stock units and stock options aligns the executive's long-term financial interests with those of the shareholders, incentivizing sustained company performance.
• Equity compensation is a standard practice for retaining key talent and motivating executives to achieve strategic objectives.

Negatives

• The equity awards do not represent immediate cash value for the executive, as they are subject to multi-year vesting schedules.
• The value of the awards is dependent on the future performance of ADMA Biologics' stock price, introducing market risk.

Risks

• The value of the granted RSUs and stock options is subject to market fluctuations of ADMA Biologics' common stock.
• Unvested RSUs and stock options may be forfeited if the reporting person's service to the company terminates before the vesting conditions are met.
• The exercise price of the stock options ($16.37) means the options will only have intrinsic value if the stock price exceeds this amount.

Future Outlook

The equity awards, consisting of RSUs and stock options, are structured with multi-year vesting schedules extending to February 9, 2030, for options and four years from their respective grant dates for RSUs. This indicates a long-term incentive structure for the executive, aligning future performance with compensation.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to a senior executive like a COO and SVP of Compliance is a common and widely accepted practice in the biotechnology and pharmaceutical industries. This form of equity compensation is designed to attract, retain, and motivate key personnel by aligning their financial success with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a standard component of executive remuneration across the biotechnology and pharmaceutical industries.
• The multi-year vesting schedule for both RSUs and stock options is consistent with common industry practices designed to incentivize long-term performance and executive retention.
• This Form 4 filing does not provide specific peer group compensation data or company performance metrics necessary for a direct quantitative comparison to specific comparable companies or projects within the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: The compensation structure for senior management can influence overall company culture and employee motivation, particularly regarding performance-based incentives.

Next Steps

• The granted RSUs will vest quarterly on each annual anniversary of the grant date over four years, subject to continued service.
• The granted stock options will vest over four years, with 25% on the one-year anniversary and the remaining 75% monthly over the next three years, becoming fully vested by February 9, 2030.

Key Dates

Keywords

ADMA Biologics, ADMA, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Beneficial Ownership, Corporate Governance